GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Veri Medtech Holdings Inc (OTCPK:VRHI) » Definitions » Intrinsic Value: Projected FCF

VRHI (Veri Medtech Holdings) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 29, 2025)


View and export this data going back to . Start your Free Trial

What is Veri Medtech Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-29), Veri Medtech Holdings's Intrinsic Value: Projected FCF is $0.00. The stock price of Veri Medtech Holdings is $0.4124. Therefore, Veri Medtech Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Veri Medtech Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

VRHI's Price-to-Projected-FCF is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.11
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Veri Medtech Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for Veri Medtech Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veri Medtech Holdings Intrinsic Value: Projected FCF Chart

Veri Medtech Holdings Annual Data
Trend Dec21
Intrinsic Value: Projected FCF
-

Veri Medtech Holdings Semi-Annual Data
Dec21
Intrinsic Value: Projected FCF -

Competitive Comparison of Veri Medtech Holdings's Intrinsic Value: Projected FCF

For the Health Information Services subindustry, Veri Medtech Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veri Medtech Holdings's Price-to-Projected-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Veri Medtech Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Veri Medtech Holdings's Price-to-Projected-FCF falls into.


;
;

Veri Medtech Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Veri Medtech Holdings  (OTCPK:VRHI) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Veri Medtech Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.4124/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Veri Medtech Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Veri Medtech Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Veri Medtech Holdings Business Description

Traded in Other Exchanges
N/A
Address
1660 International Dr, Suite 600, McClean, VA, USA, 22101
Veri Medtech Holdings Inc is a healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With a integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models.

Veri Medtech Holdings Headlines